Bajpai Vijeta, Tiwari Shashank, Mishra Anwita, Sure Rashmi, Sarode Rahul, Bharti Sujit, Pandey Himanshu, Kapoor Akhil
Department of Microbiology, Homi Bhabha Cancer Centre/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India.
Department of Anaesthesia and Critical Care, Homi Bhabha Cancer Centre/Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, India.
Microb Drug Resist. 2024 Apr;30(4):147-152. doi: 10.1089/mdr.2022.0313. Epub 2024 Feb 13.
Rapid increase in antimicrobial-resistance is leading to urgent need for newer broad-spectrum antimicrobials. Therefore, we have evaluated the antimicrobial résistance spectrum of India-discovered novel antibiotics (levonadifloxacin) against clinical isolates recovered from cancer patients. The study was conducted in the microbiology department, over a period of 1 year between May 2021 and June 2022 and 374 consecutive and nonduplicate Gram-positive (GPC) and MDR Gram Negative Bacteria (GNB) isolate were analyzed from 3,880 cancer patients in study. The identification and antimicrobial sensitivities of bacterial isolates were performed according to standard laboratory protocols by using automated identification system (VITEK-2-8.01; BioMérieux, Germany). The activity of levonadifloxacin and comparator antibiotics was evaluated using disk diffusion methods as per Clinical and Laboratory Standards Institute 2022 guidelines. The mean age of the patients were 51.6 ± 14.59 years with male: female ratio of 1.2:1. The prevalence of GPC was 167 (44.65%) and MDR-GNB was 207 (55.34%). The most common GPC was ; 97 (58.08%) followed by 66 (39.52%). In GNB, ; 93 (44.92%) was the most common followed by ; 45 (21.73%). Levonadifloxacin susceptibility was present in 98.7% methicillin-resistant and 96% methicillin-susceptible and 77.1% species. Additionally, all the fluoroquinolones-resistant isolates were susceptible to levonadifloxacin (WCK-771) except one isolate. Also, levonadifloxacin-(WCK-771) exhibits 100% susceptibility fluoroquinolone susceptible GNB, such as , , and . Interestingly, all fluoroquinolones-resistant and exhibited 100% susceptibility to levonadifloxacin (WCK-771). Levonadifloxacin (WCK-771) possesses potent activity against all the MDR Gram-positive pathogens including the coverage of susceptible and MDR and suggesting its potential utility in the management of polymicrobial infections.
抗菌耐药性的迅速增加导致对新型广谱抗菌药物的迫切需求。因此，我们评估了在印度发现的新型抗生素（左氧那氟沙星）对从癌症患者中分离出的临床菌株的抗菌谱。该研究在微生物学部门进行，于2021年5月至2022年6月的1年时间内开展，对研究中3880名癌症患者的374株连续且非重复的革兰氏阳性（GPC）菌和多重耐药革兰氏阴性菌（GNB）进行了分析。使用自动化鉴定系统（VITEK-2-8.01；德国生物梅里埃公司），根据标准实验室规程对细菌分离株进行鉴定和抗菌敏感性检测。按照临床和实验室标准协会2022年指南，采用纸片扩散法评估左氧那氟沙星和对照抗生素的活性。患者的平均年龄为51.6±14.59岁，男女比例为1.2:1。GPC的患病率为167例（44.65%），多重耐药GNB为207例（55.34%）。最常见的GPC是 ；97例（58.08%），其次是 66例（39.52%）。在GNB中， ；93例（44.92%）最常见，其次是 ；45例（21.73%）。98.7%耐甲氧西林的 、96%对甲氧西林敏感的 和77.1%的 菌株对左氧那氟沙星敏感。此外，除1株分离株外，所有耐氟喹诺酮的 分离株对左氧那氟沙星（WCK-771）敏感。而且，左氧那氟沙星-（WCK-771）对氟喹诺酮敏感的GNB，如 、 和 ，显示出100%的敏感性。有趣的是，所有耐氟喹诺酮的 和 对左氧那氟沙星（WCK-771）均表现出100%的敏感性。左氧那氟沙星（WCK-771）对所有多重耐药革兰氏阳性病原体具有强大活性，包括对敏感的 和多重耐药的 以及 的覆盖，表明其在治疗混合感染方面具有潜在用途。
